Cogent Biosciences, Inc. stock soars after bezuclastinib's strong Phase 3 results in GIST. Click for my updated look at COGT ...
Concerns about the company's future growth are likely keeping investors away.
The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...
As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...
Zacks Investment Research on MSN
Lilly Up 18% in a Month: Should You Buy, Sell or Hold the Stock?
Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, ...
Markets have turned upbeat amid optimism that the 39-day US shutdown could soon come to an end, after a weekend of dealmaking in Washington. A new bill quickly advanced in a key S ...
Wendy’s plans to close hundreds of US restaurants over the next few months in an effort to boost its profit. The Dublin, Ohio ...
The prolonged shutdown has taken a toll on consumer confidence and the overall economy, with consumer sentiment dropping to ...
On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...
Q2 2026 Earnings Call November 10, 2025 4:30 PM ESTCompany ParticipantsSteven Lisi - CEO & Chairman of the BoardDouglas Larson ...
2hon MSN
Where Will Pfizer Be in 3 Years?
Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback